On Tuesday, H.C. Wainwright reaffirmed a Buy rating with a $15.00 stock price target for Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company trading on NASDAQ:OCUL. The company, now valued at $1.54 billion, has seen its stock surge over 264% in the past year.
The firm's confidence in the stock continues following a significant development in the company's clinical trials. According to InvestingPro data, analyst targets range from $14 to $22, suggesting potential upside from current levels.
Ocular Therapeutix recently achieved a milestone in its Phase 3 SOL-1 trial for AXPAXLI, an investigational treatment for wet Age-related Macular Degeneration (AMD (NASDAQ:AMD)). The trial has now fully enrolled and randomized over 300 patients, indicating strong interest in the potential therapy among the patient population.
This rapid enrollment is seen as a positive indication of the demand for new, durable treatments for wet AMD. InvestingPro analysis shows the company maintains a strong liquidity position with current assets significantly exceeding short-term obligations.
Following this update, all active clinical trial sites have shifted focus to enrolling subjects in the second registrational trial, SOL-R. In addition, Ocular Therapeutix is working on activating more clinical trial sites globally to expedite enrollment for SOL-R, which may lead to an accelerated timeline for the pivotal program of AXPAXLI.
The management team at Ocular Therapeutix anticipates releasing topline results from the SOL-1 trial in the fourth quarter of 2025. The progress reported suggests that the company is on track with its clinical development plans for AXPAXLI.
H.C. Wainwright's reiterated Buy rating and price target reflect optimism about the company's clinical advancements and the potential market demand for AXPAXLI if approved. The firm's analysis points to a promising future for Ocular Therapeutix's ongoing efforts in addressing wet AMD.
In other recent news, Ocular Therapeutix has made significant strides in its clinical trials for Axpaxli, a treatment for wet age-related macular degeneration (AMD). The company's Phase 3 superiority trial, SOL-1, has randomized over 300 patients and is expected to deliver topline data in the fourth quarter of 2025.
In parallel, the SOL-R trial, a Phase 3 non-inferiority study for the same condition, is seeing accelerated enrollment rates. These developments are backed by a robust cash position of approximately $427 million.
Ocular Therapeutix's third-quarter financial report revealed total revenue of $15.4 million, a 2.3% year-over-year increase, albeit lower than the anticipated $16.8 million. Net losses were reported at $36.5 million. The company's lead product, DEXTENZA, is projected to generate between $62 million and $67 million in revenue for the full year of 2024.
Analysts have responded to these developments. Baird maintains an Outperform rating on Ocular Therapeutix with a $17 price target, highlighting the potential for Axpaxli in the wet AMD market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.